Skin Cancer Evaluation. Simplified.
An objective, non-invasive skin cancer evaluation platform, accessible at the point of care via a handheld, point-and-click device.
DermaSensor uses light to non-invasively scan skin lesions to detect properties consistent with malignancy at a cellular and subcellular level. It’s like an ultrasound, but using light instead of sound. The intuitive handheld device provides an immediate, objective result.
![](https://www.dermasensor.com.au/wp-content/uploads/sites/6/2021/03/hiw-body-1-2.png)
Assess
Identify equivocal lesions where an objective risk assessment would be helpful.
![](https://www.dermasensor.com.au/wp-content/uploads/sites/6/2021/03/hiw-body-2-2.png)
Analyse
Use our device to analyse, and receive an "Investigate Further" or "Monitor" result.
![](https://www.dermasensor.com.au/wp-content/uploads/sites/6/2021/03/hiw-body-3-2.png)
Act
Counsel your patient on next steps using the objective result to assist in your decision making.
![Device Application](https://www.dermasensor.com.au/wp-content/uploads/sites/6/2021/10/device-appication-fade@1000.jpg)
Features
- Simple design, effortless application
- Non-invasive optical spectroscopy
- Beneath the skin, cellular-level analysis
- AI-Powered, ultra-minitiarized ESS Technology
- 97% sensitivity across common skin cancers1
- 68% decrease in missed skin cancers with use of the device2
DermaSensor’s technology holds the promise of improving early detection of skin cancer by equipping primary care providers with a tool to better assess it.
David Leffell, M.D.
Chief, Section of Dermatologic Surgery and Cutaneous Oncology, Yale School of Medicine Scientific Advisory Board, DermaSensor
![david lafell](/wp-content/uploads/sites/6/2021/07/xdavid-leffell,40800.jpg.pagespeed.ic.h7JnR2eVGj.jpg)
![David Leffell](https://www.dermasensor.com.au/wp-content/uploads/sites/6/2021/07/david-leffell@800.jpg)
With improved confidence in conducting skin cancer checks, you have the potential to significantly increase detection rates. Speak to one of DermaSensor's consultants today to arrange a 30 day trial of the DermaSensor device in your practice.
DermaSensor looks beyond the visual to improve your decision-making and confidence.
According to the results of a study with 57 GPs, skin cancer detection increases by 13% (from 81% to 94% sensitivity) when using DermaSensor, with no significant decrease in specificity.2
![](https://www.dermasensor.com.au/wp-content/uploads/sites/6/2021/11/device-animation-full-1.gif)
Footnotes
1Manolakos D et al. Clinical Validation of a Handheld Elastic Scattering Spectroscopy Artificial Intelligence Device, Presentation at American Academy of Dermatologists Innovation Academy, July 20-24, 2022.
2Thames T et al. Clinical Utility of a Handheld Elastic Scattering Spectroscopy Tool and Machine Learning on the Diagnosis and Management of Skin Cancer. Poster Presentation, STFM Annual Spring Conference, April 30-May 4, 2022.
80-0006.1 v2